Visiongain has published a new report entitled Pharma Contract Sales Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): Forecasts by Services (Personal Promotion (Promotional Sales Team, Key Account Management, Specialty Sales Teams, Vacancy Management), by Non-Personal Promotion (Contact Center, Tele-detailing, Digital Omnichannel Engagement, Medical Call Centers, Patient Support Programs, Telesampling), by Co-promotion (Product Commercialization, Marketing Research and Consulting, Territory Optimisation and Alignment, Market Access and Pricing Support, Brand Management, Co-promotion Partnerships, Mature Product Line Support), by Support Services (Training & Compliance Services, Data Analytics and CRM Support, Medical Affairs Outsourcing, Pharmacovigilance and Safety Monitoring)), by Therapeutic Areas (Oncology, Immunology, Diabetes, Cardiovascular Diseases, Respiratory Diseases, CNS Diseases, Others), by End-users (Pharmaceutical Companies, Biopharmaceutical Companies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies.

The global pharma contract sales market is estimated at US$13.03 billion in 2025 and is projected to grow at a CAGR of 12.3% during the forecast period 2025-2035.

Impact of the U.S. Trade Tariffs on the Global Pharma Contract Sales Market 

U.S. trade tariffs on pharmaceutical imports, particularly on Chinese APIs and medical components, are reshaping cost structures and decision making in the global pharma contract sales market. Higher landed costs are squeezing margins, pushing originator companies to search for leaner, more flexible commercial models. As a result, many are shifting from large in-house salesforces to outsourced or hybrid teams, using CSOs to reduce fixed costs and tailor field presence by region. Tariff uncertainty is also prompting firms to delay or re-phase launch investments, with CSOs often brought in to run targeted pilot launches instead of full-scale rollouts.  

Evolving Market Needs Drive Broadening of Pharma Service Offerings

Contract sales organisations are increasingly broadening their offerings through acquisitions, partnerships, platform development, and rebranding initiatives. This diversification helps them meet client expectations for holistic, end-to-end solutions encompassing market access, medical affairs, digital engagement, field deployment, and logistics.

EVERSANA’s merger with Waltz Health on 26 August 2025 exemplifies how integrated service lines, linking access, pricing, commercialisation, and payer engagement are being built to address evolving pharma needs.  Also, on 11 November 2024, Cencora enhanced its support for pharmaceutical companies by acquiring Public Health Expertise (PHE), a life sciences consulting firm based in France, known for its specialization in market access, real-world evidence, and health economics and outcomes research. These developments highlight a market where diversified service portfolios are becoming essential for long-term strategic partnerships with pharmaceutical companies.

How will this Report Benefit you?

Visiongain’s 399-page report provides 179 tables, 228 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analysis for the pharma contract sales market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for pharma contract sales. Get financial analysis of the overall market and different segments including type, product and service, workflow, application, indication, end-user, and capture higher market share. We believe that there are strong opportunities in this fast-growing pharma contract sales market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Data-Driven Decision Making Driving Growth in Pharma Commercial Operations

Data-driven decision-making has become a cornerstone of pharmaceutical sales and commercial strategies, creating momentum for contract sales providers that can deliver advanced analytics, CRM integration, and AI-powered insights. With fragmented sales and engagement channels, pharma companies are relying on outsourced partners to unify physician targeting, patient support, and real-time performance tracking. This shift is not only improving efficiency but also raising expectations for transparency and accountability across sales ecosystems.

Recent developments illustrate how contract sales providers are embedding data at the core of their offerings. For instance, on 10 September 2025, IQVIA launched its Clinical Trial Financial Suite (CTFS), an AI-enabled platform that streamlines budgeting, contracting, and forecasting, reducing inefficiencies in clinical-commercial workflows. Similarly, on 11 June 2025, IQVIA introduced custom-built AI agents at GTC Paris, showcasing how domain expertise coupled with advanced computing can accelerate insights and improve patient outcomes. These launches underscore how the demand for data-centric tools is directly shaping the growth of pharma contract sales, enabling partners to act not only as sales enablers but also as strategic intelligence providers.

Digital Disruption Drives New Outsourcing Models in Pharma Sales

Technology is redefining how pharmaceutical sales are executed, with contract providers at the forefront of this transformation. Automation, AI, and digital engagement tools are helping companies scale efficiently while maintaining compliance and improving targeting precision. Outsourcing these functions allows pharma to access cutting-edge platforms without heavy internal investment, making contract sales providers essential partners in driving digital transformation.

For example, on 4 August 2025, EVERSANA launched an AI-powered pharmaceutical marketing agency built on Google Cloud, delivering 80% automation in campaign management. This innovation not only reduces costs but also accelerates time-to-market for brand initiatives. Similarly, on 24 March 2025, Inizio Medical introduced iON.AI, an AI intelligence platform designed for Medical Affairs teams to improve scientific engagement and knowledge dissemination. These developments illustrate how technology and outsourcing are converging, enabling providers to move beyond traditional sales models into holistic, digitally enabled commercial strategies.

Where are the Market Opportunities?

Localisation and Regional Investment Unlock New Commercial Opportunities in Asia

Asia Pacific continues to represent one of the fastest-growing opportunities for pharma contract sales providers, fuelled by rising healthcare demand, expanding clinical infrastructure, and supportive regulatory reforms. Contract partners are increasingly embedding themselves in the region to capture growth, offering localisation strategies, digital solutions, and regional hubs that strengthen access to diverse patient populations. This expansion is not just about sales deployment but also about building trust with healthcare providers and aligning commercial strategies with local systems.

For instance, on 21 January 2025, Syneos Health signed an agreement with Kyushu University Hospital in Japan to expand clinical trial capacity into additional therapeutic areas, reinforcing its role in regional trial delivery. Similarly, on 17 February 2025, Syneos Health extended its clinical operations to Mayapada Hospital in Jakarta, Indonesia, broadening patient access and trial diversity. These moves exemplify how global players are investing in Asian infrastructure to strengthen their commercial presence, ensuring that pharma companies benefit from localised execution, reduced timelines, and expanded reach in critical markets.

Competitive Landscape

The major players operating in the pharma contract sales market are IQVIA Inc., Syneos Health, ICON plc, Inizio, EVERSANA, Uniphar | Global Sourcing, Cencora, Inc., CMIC HOLDINGS Co., LTD., EPS Corporation, Marvecs GmbH, Promoveo Health, MaBico, Sales Partnerships, Inc., QFR Solutions, Sales Focus Inc., Apodi, Amplity Inc., VANGUARD PHARMA, LLC, Mednext Pharma Pvt. Ltd., ONCALL, LLC, Granard Pharmaceutical Sales and Marketing, GTS Solution, SOFIP, and Peak Pharma Solutions Inc. These major players operating in the pharma contract sales market have adopted a range of strategies including M&A, strategic collaborations, partnerships, escalating investment in R&D, regional business expansions, and the launch of new services to strengthen their market position.

Recent Developments

• On 11^th September 2025, EVERSANA was named by Precigen Inc. as its commercialization partner for PAPZIMEOS (zopapogene imadenovec-drba), approved by the FDA in August 2025. EVERSANA supported pre-approval planning and now provides launch services, including market access, field deployment, medical affairs, and marketing.
• On 10^th September 2025, IQVIA introduced its Clinical Trial Financial Suite (CTFS), an AI-enabled platform that integrates budgeting, contracting, forecasting, and payment workflows. The system addresses inefficiencies caused by fragmented processes and offers end-to-end financial management for clinical trials.
• On 28^th August 2025, IQVIA announced a collaboration to support Flagship’s network of biopharma companies. The initiative provides access to IQVIA’s information assets, analytics, and expertise across the drug development lifecycle, helping accelerate innovation from discovery to commercialization.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 207 336 6100.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.